The antibody-drug conjugate target landscape across a broad range of tumour types

Annals of Oncology

Volumn 28, Issue 12, 2017, Pages 3083-3091

  Moek, K L ^a   de Groot, D J A ^a   de Vries, E G E ^a   Fehrmann, Rudolf S N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antibody drug conjugate; Cancer; FGmRNA profiling; Target

Indexed keywords

ANETUMAB RAVTANSINE; ANTIBODY DRUG CONJUGATE; APRUTUMAB IXADOTIN; BIVATUZUMAB MERTANSINE; BRENTUXIMAB VEDOTIN; CANTUZUMAB MERTANSINE; CANTUZUMAB RAVTANSINE; COLTUXIMAB RAVTANSINE; DENINTUZUMAB MAFODOTIN; DEPATUXIZUMAB MAFODOTIN; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; INDATUXIMAB RAVTANSINE; INDUSATUMAB VEDOTIN; INOTUZUMAB OZOGAMICIN; LABETUZUMAB GOVITECAN; LONCASTUXIMAB TESIRINE; LORVOTUZUMAB MERTANSINE; LUPARTUMAB AMADOTIN; MILATUZUMAB; MIRVETUXIMAB SORAVTANSINE; PINATUZUMAB VEDOTIN; POLATUZUMAB VEDOTIN; ROVALPITUZUMAB TESIRINE; TELISOTUZUMAB VEDOTIN; TRASTUZUMAB DUOCARMAZINE; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VADASTUXIMAB TALIRINE; VORSETUZUMAB MAFODOTIN; ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOTOXIN; MESSENGER RNA;

ARTICLE; CANCER INCIDENCE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; HUMAN; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASM; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RARE DISEASE; SQUAMOUS CELL LUNG CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER; ANTIBODY PRODUCTION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANTIBODIES; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTOXINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA, MESSENGER;

EID: 85042149609     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx541     Document Type: Article

References (12)

1. Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol 2016; 27: 2168-2172
2. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
3. Fehrmann RS, Karjalainen JM, Krajewska M et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nat Genet 2015; 47: 115-125
4. Barrett T, Wilhite SE, Ledoux P et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013; 41: D991-D995
5. Bense RD, Sotiriou C, Piccart-Gebhart MJ et al. Relevance of tumorinfiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst 2017; 109: 1-9
6. Lamberts LE, de Groot DJ, Bense RD et al. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget 2015; 6: 28164-28172
7. Yardley DA, Weaver R, Melisko ME et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol 2015; 33: 1609-1619
8. Gaber R, Watermann I, Kugler C et al. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. Diagn Pathol 2014; 9: 165
9. Hartmans E, Orian-Rousseau V, Matzke-Ogi A et al. Functional genomic mRNA profiling of colorectal adenomas: identification and in vivo validation of CD44 and splice variant CD44v6 as molecular imaging targets. Theranostics 2017; 7: 482-492
10. Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 2015; 32: 3494-3507
11. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016; 17: e254-e262
12. Beck A, Goetsch L, Dumontet C, Corvaiä N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017; 16: 315-337